Your gift will be matched today.
Treatments for childhood nodular lymphocyte-predominant HL
The following are treatment options for childhood nodular lymphocyte-predominant Hodgkin lymphoma (HL). The healthcare team will suggest treatments based on your child’s needs and work with you to develop a treatment plan. Treatments are based on the stage of the cancer.
Treatments for stage I
Surgery to remove the lymph nodes is the main treatment for stage I nodular lymphocyte-predominant childhood HL when doctors think the tumour can be completely removed, or resected. The surgeon removes only the lymph nodes that are known to have cancer. After surgery, the healthcare team will follow the child closely for signs that the cancer has come back, or recurred.
Surgery to remove the lymph nodes is also called lymph node dissection. Find out more about lymph node dissection.
Treatments for all other stages
The following treatments may be offered for stage II, III or IV nodular lymphocyte-predominant childhood HL.
Chemotherapy is the primary treatment for stages II to IV of nodular lymphocyte-predominant childhood HL. It may be given alone or it may be followed by radiation therapy.
Chemotherapy combinations used include:
- COPP/ABV – cyclophosphamide (Cytoxan, Procytox), vincristine (Oncovin), prednisone, procarbazine hydrochloride (Matulane), doxorubicin (Adriamycin), bleomycin (Blenoxane) and vinblastine (Velbe)
- VAMP – vincristine, doxorubicin, methotrexate and prednisone
- DBVE – doxorubicin, bleomycin, vincristine and etoposide (Vepesid, VP-16)
After chemotherapy, low-dose radiation therapy may be given to areas that have cancer. The type of radiation therapy used is external beam radiation therapy. During external beam radiation therapy, a machine directs radiation through the skin to the tumour and some of the tissue around it.
Many children with Hodgkin lymphoma enter a clinical trial that is tailored to the risk group or stage of their disease. The clinical trial protocol outlines the chemotherapy drugs and dosages used. Find out more about clinical trials.
Together we can reduce the burden of cancer
Last year, we only had the resources available to fund 40% of high-priority research projects. Imagine the impact we could have if we were able to fund 100%.